Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Key Takeaways Mechanism of action: Triple-hormone agonist targeting GLP-1, GIP, and glucagon receptors Efficacy: 24.2% average weight loss in 48 weeks UK availability: 2026 (UK), potentially 2027 (FDA) Common side effects: Nausea, diarrhoea, vomiting, constipation Safety profile: Similar to existing GLP-1 medications but with concerns about rapid weight loss By entering I agree to the Terms and Conditions
Retatrutide (LY-3437943): Eli Lilly Retatrutide is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the GLP-1 receptor and the glucagon receptor
Wound healing involves a multistep process, including cell proliferation, migration, tube formation, and remodeling
These side effects also tend to decrease with continued use of the drug
US$ 29.50
US$ 22.17
US$ 25.85
US$ 25.67
US$ 22.53
US$ 25.99
US$ 22.32
US$ 29.49
US$ 28.54
US$ 26.11
US$ 26.97
